Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02932644
Other study ID # 3-3013-930/1/
Secondary ID
Status Completed
Phase N/A
First received October 12, 2016
Last updated October 12, 2016
Start date October 1999
Est. completion date October 2016

Study information

Verified date October 2016
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Health and Medicines AuthorityDenmark: Danish Dataprotection Agency
Study type Observational

Clinical Trial Summary

The aim of the study is to evaluate cardiovascular events during long-term follow-up in Rheumatoid Arthritis. The primary outcome "any cardiovascular event" will be evaluated using systematic audits of patient records, and will be associated to low levels of vitamin D at baseline, to investigate the hypothesis that low levels of vitamin D can be part of a prediction model for cardiovascular disease in Rheumatoid Arthritis.


Description:

Cardiovascular morbidity and mortality is increased in patients with rheumatoid arthritis (RA), and among these patients, the prevalence of hypo-vitaminosis D is high. Low levels of vitamin D have been associated with elevated cardiovascular risk in healthy subjects. The objective of this study is to evaluate the risk of cardiovascular events in patients having low 25OHD-total levels at baseline compared to patients with sufficient levels, in an aggressively treated closed cohort of early-diagnosed RA patients.

The primary outcome will be the proportion of patients with any cardiovascular event, evaluated using systematic journal audits. Logistic regression models will be applied to test the hypothesis that there are more cardiovascular events in patients enrolled with a low level of vitamin D (< 50 nmol/l). Secondarily, Cox regression models, based on survival analysis, will be applied, to determine the extent to which independent variables (including different levels of vitamin D at baseline) predict not only whether a cardiovascular event occur, but also when it will occur.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date October 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: Fulfilling ACR1987 (American College of Rheumatology 1987 classification criteria for Rheumatoid Arthritis) criteria for RA, disease duration < 6 months, 2 or more swollen joints and age between 18 and 75 years -

Exclusion Criteria: Glucocorticoid treatment 4 weeks prior to inclusion, previous use of DMARDs, malignancy, diastolic blood pressure > 90 mm Hg, elevated serum creatinine, infections with parvovirus B19, Hepatitis B, C and HIV, and any condition contraindicating the study medication.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Other:
Baseline serum vitamin D level below 50 nmol/l
There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
Baseline serum vitamin D level at or above 50 nmol/l
There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis

Locations

Country Name City State
n/a

Sponsors (6)

Lead Sponsor Collaborator
Odense University Hospital Odense Patient Explorative data Network (OPEN), Pfizer, Region of Southern Denmark, The Danish Rheumatism Association, University of Southern Denmark

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiovascular event Events will be recorded using systematic journal audits. A cardiovascular event will be further subclassified as shown in the secondary outcome measures, but for primary outcome measures; any cardiovascular event, including death, will serve as "an event" Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute cardiovascular hospitalisation due to Myocardial Ischamia Non-fatal or fatal myocardial infarction, defined by National and International Guidelines (Thygesen et al. 1581-98).
Fatal myocardial infarction is defined as primary fatal event within 7 days, documented post mortem by autopsy, or by the definition of myocardial infarction according to European Guidelines (Thygesen et al. 1581-98) Death of myocardial infarction as a consequence of medical examination/procedure/surgery will be classified as procedure related death.
Acute Coronary Syndrome (ACS) includes acute ischaemic symptoms with eventual elevation in biomarkers or electrocardiographic changes which does not fulfil the criteria of acute myocardial infarction.
Angina Pectoris. Revascularisation procedures (Percutaneous Coronary Intervention (PCI) or Coronary bypass Graft (CABG).
Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute cardiovascular hospitalisation due to hearth failure Patients with non-elective hospitalisation or death, minimum one overnight stay, with symptoms or findings of heart failure.
Death due to heart failure is defined as escalating heart failure symptoms prior to death.
Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute cardiovascular hospitalisation due to stroke Cerebral haemorrhage, cerebral thromboembolism, Transitory Cerebral Ischemia (TCI) and others Stroke is defined as abrupt severe neurologic deficits, eventually with computer tomographic (CT) documentation. Death within 14 days after symptom-onset of stroke, and without other obviously reasons, is classified as caused by stroke Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute cardiovascular hospitalisation due to arrhythmias Atrial fibrillation or flutter, supraventricular tachycardia and others. Ventricular tachycardia, ventricular fibrillation and others. Death due to arrhythmia requires documentation, e.g. telemetric transcript, pacemaker or electrocardiogram Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute cardiovascular hospitalisation due to Procedure-related cardiovascular event Any cardiovascular event within 24 hours after cardiovascular medical examination/procedure/surgery. Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute cardiovascular hospitalisation due to other reasons Hospitalisation caused by other cardiovascular events, e.g. pulmonary embolism, rupture of aortic aneurism etc. Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute cardiovascular hospitalisation due to supposed cardiovascular reason Hospitalisation without any documented non-cardiovascular cause. All deaths which are not defined by the cardiovascular reasons mentioned above, and who are not caused by well-documented non-cardiovascular death.
All deaths without known reason
Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute non-cardiovascular hospitalisation due to cancer Acute hospitalisation due to cancer Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute non-cardiovascular hospitalisation due to infection Acute hospitalisation due to infection Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute non-cardiovascular hospitalisation due to respiratory disease Acute hospitalisation due to respiratory disease Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute non-cardiovascular hospitalisation due to trauma Acute hospitalisation due to trauma Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute non-cardiovascular hospitalisation due to suicide Acute - hospitalisation due to suicide Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Acute non-cardiovascular hospitalisation due to other reasons Acute hospitalisation du to other non-cardiovascular reasons, than those previous mentioned Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Elective cardiovascular hospitalisation due to myocardial ischemia Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Elective cardiovascular hospitalisation due to arrhythmia Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Elective cardiovascular hospitalisation due to heart failure Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Elective cardiovascular hospitalisation due to other cardiovascular reasons Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Elective non-cardiovascular hospitalisation due to cancer Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Elective non-cardiovascular hospitalisation due to infection Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Elective non-cardiovascular hospitalisation due to respiratory disease Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Elective non-cardiovascular hospitalisation due to trauma Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Elective non-cardiovascular hospitalisation due to suicide Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Witnessed, sudden cardiovascular death Death is witnessed and abrupt within one hour after symptom-onset Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Non-witnessed, sudden cardiovascular death Non-witnessed death with no obvious non-cardiovascular reasons (found death) Observed in the time-period from inclusion to October the 10th 2016 No
Secondary Non-sudden cardiovascular death Death due to any of the cardiovascular caused previously mentioned, more than one hour after symptom-onset Observed in the time-period from inclusion to October the 10th 2016 No
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4